212 related articles for article (PubMed ID: 35549881)
1. Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini-Review.
Patnaik SK; Chandrasekar MJN; Nagarjuna P; Ramamurthi D; Swaroop AK
Mini Rev Med Chem; 2022 Oct; 22(22):2831-2846. PubMed ID: 35549881
[TBL] [Abstract][Full Text] [Related]
2. Peptides for Dual Targeting of ErbB1 and ErbB2: Blocking EGFR Cell Signaling Transduction Pathways for Cancer Chemotherapy.
Patnaik SK; Swaroop AK; Nagarjuna P; Nanjan MJ; Chandrasekar MJN
Curr Mol Pharmacol; 2024; 17(1):e240223214012. PubMed ID: 36843255
[TBL] [Abstract][Full Text] [Related]
3. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
5. Virtual high throughput screening of natural peptides against ErbB1 and ErbB2 to identify potential inhibitors for cancer chemotherapy.
Patnaik SK; Ayyamperumal S; Jade D; Palathoti N; Akey KS; Jupudi S; Harrison MA; Ponnambalam S; Mj N; Mjn C
J Biomol Struct Dyn; 2023 Jun; ():1-24. PubMed ID: 37387589
[TBL] [Abstract][Full Text] [Related]
6. ErbB Receptors and Cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract][Full Text] [Related]
7. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
Feroz K; Williams E; Riese DJ
Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of resistance to HER family targeting antibodies.
Kruser TJ; Wheeler DL
Exp Cell Res; 2010 Apr; 316(7):1083-100. PubMed ID: 20064507
[TBL] [Abstract][Full Text] [Related]
9. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
[TBL] [Abstract][Full Text] [Related]
10. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE
Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690
[TBL] [Abstract][Full Text] [Related]
11. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
[TBL] [Abstract][Full Text] [Related]
12. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
13. Targeting ErbB receptors in high-grade glioma.
Berezowska S; Schlegel J
Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
[TBL] [Abstract][Full Text] [Related]
14. Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes.
Eldridge S; Guo L; Mussio J; Furniss M; Hamre J; Davis M
Toxicol Sci; 2014 Oct; 141(2):547-59. PubMed ID: 25055963
[TBL] [Abstract][Full Text] [Related]
15. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
Choi BK; Fan X; Deng H; Zhang N; An Z
Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
[TBL] [Abstract][Full Text] [Related]
16. Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.
Friedländer E; Arndt-Jovin DJ; Nagy P; Jovin TM; Szöllosi J; Vereb G
Cytometry A; 2005 Oct; 67(2):161-71. PubMed ID: 16163699
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
Reid A; Vidal L; Shaw H; de Bono J
Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of the epidermal growth factor receptor in human cancer.
Dhomen NS; Mariadason J; Tebbutt N; Scott AM
Crit Rev Oncog; 2012; 17(1):31-50. PubMed ID: 22471663
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]